FDA Panel to Weigh Limited Data on Combo for Healthcare-Acquired Pneumonia
(MedPage Today) -- Data from small trials will determine whether an FDA advisory panel recommends the agency approve sulbactam‐durlobactam for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by Acinetobacter...
Source: MedPage Today Public Health - Category: American Health Source Type: news
More News: Acinetobacter | American Health | Bacterial Pneumonia | Hospitals | International Medicine & Public Health | Pneumonia